Consumer Health: Gentlemen, are you doing your Kegels?
June is Men's Health Month, which makes this a good time to learn more about the benefits of Kegels for men. Kegel exercises, also known as pelvic floor muscle training, can prevent or control urinary incontinence and other pelvic floor problems. For women, Kegel exercises may be suggested for some incontinence problems, including during pregnancy and after childbirth. But Kegels aren't just for women. For men, Kegel exercises can strengthen the pelvic floor muscles, which… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - June 17, 2022 Category: Databases & Libraries Source Type: news

Surgeons May Underestimate Recovery From Incontinence Operation Surgeons May Underestimate Recovery From Incontinence Operation
An analysis found no way to predict which patients will take longer to return to work and other activities after midurethral sling procedures.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 13, 2022 Category: Consumer Health News Tags: Ob/Gyn & Women ' s Health News Source Type: news

Longer-term Data from CARTITUDE-1 Study Demonstrate Continued Deep and Durable Responses to CARVYKTI ™ (ciltacabtagene autoleucel) in Heavily Pretreated Patients with Relapsed or Refractory Multiple Myeloma
CHICAGO, ILLINOIS, June 4, 2022 – – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today updated results from the Phase 1b/2 CARTITUDE-1 study evaluating the efficacy and safety of CARVYKTI™ (ciltacabtagene autoleucel; cilta-cel), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy. The study included patients with relapsed or refractory multiple myeloma (RRMM) who had received >3 lines of therapy including a proteasome inhibitor (PI), an anti-CD38 monoclonal antibody and an immunomodulatory agent (IMiD) or were double refractory to an IMiD and PI a...
Source: Johnson and Johnson - June 4, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen to Highlight Science, Innovation and Advances in Robust Oncology Portfolio and Pipeline Through More Than 60 Data Presentations at ASCO and EHA
RARITAN, N.J., May 31, 2022 — The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that new research and data from its robust oncology portfolio and pipeline of investigational therapies will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 3-7 in Chicago, and the European Hematology Association (EHA) 2022 Congress taking place in Vienna, Austria, June 9-12. More than 60 presentations from company-sponsored studies across the two congresses, including 14 oral presentations, will feature new data and updates for both approved and investigation...
Source: Johnson and Johnson - May 31, 2022 Category: Pharmaceuticals Source Type: news

Thinx names new CEO
Thinx Inc, a New York company that makes reusable period and incontinence underwear, has appointed Meghan Davis as its chief executive officer. Current CEO Maria Molland will step down June 30 to spend time with her young children, the company announced. In a LinkedIn post, Molland said she made the decision to leave the company after multinational consumer goods company Kimberly Clark (NYSE: KMB), maker of brands including Kotex and Dep end, agreed in February to acquire a majority stake in Thinx… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - May 26, 2022 Category: American Health Authors: Anne Stych Source Type: news

Thinx names new CEO
Thinx Inc, a company that makes reusable period and incontinence underwear, has appointed Meghan Davis as its chief executive officer. Current CEO Maria Molland will step down June 30 to spend time with her young children, the company announced. In a LinkedIn post, Molland said she made the decision to leave the company after multinational consumer goods company Kimberly Clark (NYSE: KMB), maker of brands including Kotex and Dep end, agreed in February to acquire a majority stake in Thinx for an… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - May 26, 2022 Category: Pharmaceuticals Authors: Anne Stych Source Type: news

New Data From Two Large Studies Reinforce Effectiveness of Dual Pathway Inhibition (DPI) with XARELTO ® (rivaroxaban) Plus Aspirin in Patients with Coronary Artery Disease (CAD) and/or Peripheral Artery Disease (PAD)
RARITAN, N.J., May 23, 2022 – Findings from the XARELTO® (rivaroxaban) Phase 3 COMPASS Long-Term Open Label Extension (LTOLE) study and the XARELTO® in Combination with Acetylsalicylic Acid (XATOA) registry have been published in the European Society of Cardiology’s (ESC) European Heart Journal, Cardiovascular Pharmacotherapy. Additionally, the XATOA registry was presented at the American Congress of Cardiology’s 71st Annual Scientific Session (ACC.22). These studies provide further evidence supporting the role of dual pathway inhibition (DPI) with the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 100 mg...
Source: Johnson and Johnson - May 23, 2022 Category: Pharmaceuticals Source Type: news

Food Insecurity Linked With Urge Urinary Incontinence
(MedPage Today) -- NEW ORLEANS -- Adults with self-reported food insecurity were significantly more likely to have a history of urge urinary incontinence (UUI), a large retrospective review showed. Overall, food insecurity increased the odds... (Source: MedPage Today OB/GYN)
Source: MedPage Today OB/GYN - May 16, 2022 Category: OBGYN Source Type: news

Surgery for stress urinary incontinence in women
(Source: MayoClinic.com Full Feed)
Source: MayoClinic.com Full Feed - May 14, 2022 Category: Consumer Health News Source Type: news

More Inflammatory Foods, More Fecal Incontinence?
(MedPage Today) -- Older women who consumed a proinflammatory diet had a greater risk of fecal incontinence, prospective data from the Nurses' Health Study found. In analyses that adjusted for dietary fiber and other relevant covariates, those... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - May 6, 2022 Category: Gastroenterology Source Type: news

For Durham entrepreneur, helping patients with prostate cancer is personal
A Durham startup hopes to change the lives of patients with prostate cancer – taking incontinence out of the equation when they’re deciding their treatment options. Levee Medical, which just closed on more than $1 million in outside capital, is moving quickly – possibly less than two years away from having its urological devices available to patients, executives sai d. It’s the brainchild of Bruce Choi, its chief technology officer. Choi, a serial entrepreneur, started  his career at… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - May 2, 2022 Category: Health Management Authors: Lauren Ohnesorge Source Type: news

The Connection Between IBD and Aging
Inflammatory bowel disease (IBD) has long been thought of as an ailment of middle, or even young, adulthood. The chronic illness—which includes Crohn’s disease and ulcerative colitis, and can cause abdominal pain, diarrhea, bleeding, and decreased quality of life—impacts about 3.1 million people in the U.S. However, it is far from a disease only of the young and middle-aged. More than a quarter of people with IBD are elderly, a figure that is projected to climb to 30% by 2030, according to a 2021 Gastroenterology & Hepatology article. Even more underappreciated is the growing population of people who ...
Source: TIME: Health - April 8, 2022 Category: Consumer Health News Authors: Katherine Harmon Courage Tags: Uncategorized Disease healthscienceclimate Source Type: news

Data from New VOYAGER PAD Analyses at ACC.22 Reinforce Benefit of XARELTO ® (rivaroxaban) Plus Aspirin in Patients with Peripheral Artery Disease (PAD) and Various Co-Morbid Conditions
RARITAN, N.J., April 1, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from new analyses from the Phase 3 VOYAGER PAD clinical trial reinforcing the benefit of the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) in reducing severe vascular events in patients with PAD after lower-extremity revascularization (LER), a procedure that restores blood flow to the legs. Data from the two analyses demonstrate the role that the XARELTO® vascular dose plays in PAD patients with and without chronic kidney disease (CKD) and in PAD patients with and ...
Source: Johnson and Johnson - April 1, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

Newer Mesh Slings for Stress Incontinence a Safe, Effective Option for Women: Study
Title: Newer Mesh Slings for Stress Incontinence a Safe, Effective Option for Women: StudyCategory: Health NewsCreated: 3/31/2022 12:00:00 AMLast Editorial Review: 4/1/2022 12:00:00 AM (Source: MedicineNet Womens Health General)
Source: MedicineNet Womens Health General - April 1, 2022 Category: OBGYN Source Type: news

Mini-Slings Noninferior to Mid-Urethral Slings for Stress UI in Women
THURSDAY, March 31, 2022 -- Single-incision mini-slings are noninferior to mid-urethral slings for women with stress urinary incontinence, according to a study published in the March 31 issue of the New England Journal of Medicine. Mohamed... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 31, 2022 Category: Pharmaceuticals Source Type: news